Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMECRX1)

Drug Name
Bivalirudin Drug Info
Synonyms
128270-60-0; Angiomax; Hirulog; bivalirudinum; bivalirudina; Bivalirudin Trifluoroacetate; BG-8967; UNII-TN9BEX005G; BG8967; Bivalirudin Trifluoacetate; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; CHEBI:59173; Hirulog-1; Angiox; Bivalirudina; Bivalirudine; Bivalirudinum; The Medicines Company brand of bivalirudin; BG 8967; Angiomax (TN); HS-2004; Bivalirudin [USAN:BAN:INN]; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
Indication
Disease Entry ICD 11 Status REF
Thrombocytopenia 3B64 Approved [1]
Therapeutic Class
Antithrombotic Agents
Cross-matching ID
PubChem CID
16129704
ChEBI ID
CHEBI:59173
CAS Number
CAS 128270-60-0
TTD Drug ID
DMECRX1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Coagulation factor IIa (F2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Argatroban DMFI46A Thrombosis DB61-GB90 Approved [7]
Pyridoxal Phosphate DMO2K0J Malnutrition 5B50-5B71 Approved [8]
Ximelegatran DMU8ANS Myocardial infarction BA41-BA43 Approved [9]
Dabigatran DMDI6R4 Stroke 8B20 Approved [10]
Desirudin Recombinant DM2BTFN Coagulation defect 3B10.0 Approved [11]
Human prothrombin complex concentrate DMPHVQ1 Bleeding disorder GA20-GA21 Approved [12]
Lepirudin DM1I3D5 Thrombocytopenia 3B64 Approved [13]
Anisindione DM2C48U Coagulation defect 3B10.0 Approved [14]
ATryn antithrombin DM79Y2T Multiple sclerosis 8A40 Approved [15]
Hirudin DMYOC29 N. A. N. A. Phase 4 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Trypanosoma Trypanothione reductase (Trypano TPR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [17]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [18]
CONESSINE DM4VYP0 Discovery agent N.A. Investigative [19]
Maleic Acid DM4L0R7 Discovery agent N.A. Investigative [20]
1-(2'-chlorophenyl)penta-1,4-dien-3-one DMKTZSY Discovery agent N.A. Investigative [21]
CEPHARANTINE DMCE3NA Discovery agent N.A. Investigative [19]
Trypanothione DMDUGQ1 Discovery agent N.A. Investigative [18]
N-(5-chloro-2-(phenylthio)phenyl)butyramide DMHZ256 Discovery agent N.A. Investigative [22]
N1,N2-bis(dihydrocaffeoyl)spermine DMSDVGQ Discovery agent N.A. Investigative [19]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Myeloperoxidase (MPO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dapsone DM4LT8A Acne vulgaris ED80 Approved [23]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [24]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [23]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [23]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [25]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [26]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [27]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [28]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [29]
Propylthiouracil DM6D7N8 Hyperthyroidism 5A02 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By C-reactive protein (CRP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lidocaine DML4ZOT Anaesthesia 9A78.6 Approved [23]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [31]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [32]
Quercetin DM3NC4M Obesity 5B81 Approved [33]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [34]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [35]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [36]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [37]
Tibolone DM78XFG Anabolic metabolism 5C50-5C8Z Approved [38]
Testosterone DM7HUNW Hot flushes GA30 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Proteinase-activated receptor 1 (F2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [40]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [41]
Selenium DM25CGV N. A. N. A. Approved [42]
Quercetin DM3NC4M Obesity 5B81 Approved [43]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [44]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [45]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [46]
Lenalidomide DM6Q7U4 Adult T-cell leukemia/lymphoma Approved [47]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [47]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Proteinase-activated receptor 4 (F2RL3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [50]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [51]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor IIa (F2) TT6L509 THRB_HUMAN Inhibitor [2]
Trypanosoma Trypanothione reductase (Trypano TPR) TTRTKPV TYTR_TRYBB Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Gene/Protein Processing [4]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Gene/Protein Processing [5]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Gene/Protein Processing [6]
Proteinase-activated receptor 4 (F2RL3) OTUNAKDB PAR4_HUMAN Gene/Protein Processing [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6470).
2 New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
3 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8.
4 The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis. 2005 Sep;16(6):401-5. doi: 10.1097/00019501-200509000-00010.
5 Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31.
6 Bivalirudin: a new promising direct antithrombin. Indian Heart J. 2007 May-Jun;59(3):288-94.
7 Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
8 New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
9 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
10 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
13 Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
14 Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
15 Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
16 Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.
17 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
18 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19 The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95.
20 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
21 Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem. 2005 Nov 17;48(23):7400-10.
22 Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class ... J Med Chem. 2005 Dec 15;48(25):8087-97.
23 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
24 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
25 An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivity. Toxicol Lett. 2017 Oct 5;280:48-56.
26 Differentiation between stoichiometric and anticatalytic antioxidant properties of benzoic acid analogues: a structure/redox potential relationship study. Chem Biol Interact. 2013 Nov 25;206(2):194-203.
27 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
28 Effect of anti-rheumatic drugs on the release of lysosomal enzymes from human leukocytes. Z Rheumatol. 1984 Jan-Feb;43(1):23-6.
29 Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. Cancer Res. 2005 Sep 1;65(17):7847-55. doi: 10.1158/0008-5472.CAN-05-1053.
30 Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin Immunol. 2007 Feb;122(2):187-93. doi: 10.1016/j.clim.2006.09.011. Epub 2006 Oct 27.
31 C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 3;18(18):2434-7.
32 Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
33 The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
34 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
35 Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
36 The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):286-97. doi: 10.1185/03007997509114779.
37 Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
38 Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
39 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
40 Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
41 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
42 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
43 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
44 Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res. 2012 Jun 15;18(12):3366-76.
45 Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002.
46 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
47 Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005 Apr 15;105(8):3286-94. doi: 10.1182/blood-2004-06-2101. Epub 2004 Dec 23.
48 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
49 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
50 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
51 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.